Caitlyn Fitzpatrick

Prisons are breeding grounds for STIs, including HIV. What can fix that?

Richard A. Chazal, MD, who was the ACC president at the time of the of the most recent ACC conference, revealed which presented studies he believes could change medical practice in the near future. He also discussed how low LDL cholesterol level guidelines will go.

Researchers are hopeful that their new technique could cure HIV.

Doctors should have an honest discussion with patients who exhibit red flags showing that they should not be given opioids, Larry Greenblatt, MD, of Duke University School of Medicine said at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

Meredith McCormack, MD, MHS, talked about managing asthma and COPD in the primary care setting and when it’s time to refer a patient to a specialist at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

Hepatitis C diagnoses are rarely made by a specialist, said Norman Sussman, MD. He explained how the telehealth program, Project ECHO, can help primary care physicians better manage patients with the virus at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

An alarming number of adolescents have multiple sex partners in one day.

What was designed to make physicians’ lives easier have caused major frustration. Bob Wachter, MD, professor and chair of the Department of Medicine at the University of California, San Francisco (UCSF) talked with MD Magazine about the issues surrounding electronic health records (EHRs).

Just how serious is physician burnout? Lisa Ellis, MD, chief medical officer at Medical College of Virginia Physicians (MCVP) at Virginia Commonwealth University, provided some startling statistics at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

British researchers find strong link between hepatitis B, C and Parkinson's.

Early HIV infection spells trouble for health outcomes.

Robert Roswell, MD, of NYU School of Medicine, discussed how much a physician's gut really comes into play when diagnosing chest pain at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

Doug Paauw, MD, attends the American College of Physicians Internal Medicine Meeting to provide an update on drug interactions and side effects prominent every year. At this year’s meeting (ACP 2017), Paauw went over some of those serious drug interactions with MD Magazine.

For Americans, a BMI of 25 means they are overweight. However, a BMI of 23.5 means overweight for Asians. David O’Dell, MD, of the University of Nebraska Medical Center explains why this matters at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

When a patient comes strolling into your office at 4:30 p.m. on a Friday wanting an opioid prescription, that could be a red flag, Suresh Reddy, MD, professor of palliative care at the University of Texas MD Anderson Cancer Center told MD Magazine.

The use of the chest x-ray for diagnosing bacterial pneumonia and the role of antibiotics in infected patients have been hot topics in community-acquired pneumonia. Scott Flanders, MD, gave an update at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

Diana McNeill, MD, of Duke University Medical Center moderated a panel at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California. The topic of discussion? Personalized care in type 2 diabetes.

Heidi Combs, MD, says that many patients present to the primary care office thinking that they have other health problems when the diagnosis is really anxiety or depression. She discussed the topic at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

The MD Magazine editors rounded up the 10 best stories from this month.

Using the database from the 40-country, double-blind phase 3 ARISTOTLE study, which has been around for over 5 years, a sub-analysis was conducted by Renato Lopes, MD, PhD, professor of Medicine at Duke University in Durham, North Carolina and colleagues.

It’s a discussion that even the most seasoned physicians might struggle with—when is it time to talk end-of-life care? Ami Bhatt, MD, director of the Adult Congenital Heart Disease Program at Massachusetts General Hospital (MGH) explained both sides of the debate for patients with adult congenital heart disease.

Some women may have suffered with cardiovascular problems since birth while others don’t find out until pregnancy unmasks the condition. Doreen DeFaria Yeh, MD, discusses the importance of merging physicians from cardiology and obstetrics.

Compared with warfarin, are direct oral anticoagulants (DOACs), including apixaban, dabigatran, and rivaroxaban, better at reducing stroke and major bleeding risks in patients with non-valvular atrial fibrillation? Alpesh Amin, MD, professor of medicine at the University of California, Irvine breaks it down at ACC 2017 in Washington, District of Columbia.

NSAIDs may help a variety of painful conditions, but come with heart risks.

Steven Zelenkofske, DO, vice president of US Medical Affairs at AstraZeneca, talked with MD Magazine about the CVD-REAL study where researchers examined patients with type 2 diabetes taking the new class of diabetes drug, SGLT-2 inhibitors. Positive outcomes were reported with dapagliflozin, canagliflozin, and empagliflozin.

While TB cases are decreasing, HIV/TB coinfection cases are on the rise.

Paul Burton, MD, PhD, revealed results from the phase 3 EINSTEIN CHOICE trial at the 66th Scientific Session of the American College of Cardiology (ACC 2017) in Washington, District of Columbia. The trial examined the use of rivaroxaban (Xarelto/Janssen) or aspirin as extended treatment in patients with VTE.

Excitement has been surrounding PCSK9 inhibitors due to high efficacy in lowering cholesterol. However, two reports in 2015 found that two of these drugs (evolocumab and alirocumab) were linked to cognitive issues. A phase 3 trial at ACC 2017 set out to find if that's actually the case.

Scott Solomon, MD, director of Noninvasive Cardiology at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, detailed study results for sacubitril/valsartan the first angiotensin receptor neprilysin inhibitor to be approved by the FDA for its indication.

Jay Edelberg, MD, PhD, discusses the alirocumab phase 3 trial results at ACC 2017. “The results demonstrated that genetics really teach us a lot,” he said, noting that the majority of high-risk patients were able to achieve their treatment goals with just the 75 mg dose.